Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Patrikidou, Anna ^a   Vlachostergios, Panagiotis J ^a   Voutsadakis, Ioannis A ^a   Hatzidaki, Eleana ^a   Valeri, Rosalia Maria ^b   Destouni, Chariklia ^b   Apostolou, Effie ^c   Daliani, Danai ^a   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; NEUROPEPTIDE; PROTEASOME;

ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 79955788758     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-13     Document Type: Article

References (34)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
2. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004, 64:5036-5043. 10.1158/0008-5472.CAN-03-2707, 15289299.
3. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785. 10.1016/S0092-8674(94)90482-0, 8087845.
4. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107:241-246. 10.1172/JCI11991, 199203, 11160144.
5. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Steins H, Sundays ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991, 88:10662-10666. 10.1073/pnas.88.23.10662, 52990, 1660144.
6. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!. Blood 1993, 84:1052-1070.
7. Kenny AJ. Endopeptidase-24.11: putative substrates and possible roles. Biochem Soc Trans 1993, 21:663-668.
8. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc mettaloendopeptidases: genomics and function. BioEssays 2001, 23:261-269. 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K, 11223883.
9. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Investig 1993, 91:1969-1973. 10.1172/JCI116417, 288193, 8486767.
10. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001, 61:3294-3298.
11. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res 2001, 7:1370-1377.
12. Nanus DM. Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res 2003, 9:6307-6309.
13. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944-949. 10.1038/nm0995-944, 7585222.
14. Papandreou CN, Usmani BA, Geng Y, Bogenreider T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4:50-57. 10.1038/nm0198-050, 9427606.
15. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999, 161:674-679. 10.1016/S0022-5347(01)61993-1, 9915481.
16. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res 2000, 6:1969-1677.
17. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2001, 18:471-479.
18. Carter AB, Monick MM, Hunninghake GW. Lipopolysaccharide-induced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PC-PLC-dependent. Am J Respir Cell Mol Biol 1998, 18:384-391.
19. Ouadrhiri Y, Pilette C, Monteiro RC, Vaerman JP, Sibille Y. Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-kappaB. Am J Respir Cell Mol Biol 2002, 26:315-332.
20. Thanos D, Maniatis T. Identification of the rel family members required for virus induction of the human beta interferon gene. Mol Cell Biol 1995, 15:152-164. 231925, 7799921.
21. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumours with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121. 10.1200/JCO.2004.02.106, 15169797.
22. Aprikian AG, Tremblay L, Han K, Chevalier S. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997, 72:498-504. 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.0.CO;2-8, 9247295.
23. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000, 106:1399-1407. 10.1172/JCI10536, 381465, 11104793.
24. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001, 12(Suppl. 2):S145-S152.
25. Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promises and the challenge of molecularly targeted therapy. Can J Physiol Pharmacol 2008, 86:473-484. 10.1139/Y08-058, 18758494.
26. Wilson TJ, Singh RK. Proteases as modulators of tumor-stromal interaction: Primary tumors to bone metastases. Biochim Biophys Acta 2008, 1785:85-95. 2418859, 18082147.
27. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20:4188-4197. 10.1038/sj.onc.1204535, 11464285.
28. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002, 22:2862-2870. 10.1128/MCB.22.8.2862-2870.2002, 133743, 11909978.
29. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gélinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002, 52:183-200. 10.1002/pros.10082, 12111695.
30. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002, 115(Pt 1):141-151.
31. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004, 10:5501-5507. 10.1158/1078-0432.CCR-0571-03, 15328189.
32. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000, 6:1664-1670.
33. Grant ES, Brown T, Roach A, Williams BC, Habib FK. In vitro expression of endothelin-1 (ET-1) and the ETA and ETB ET receptors by the prostatic epithelium and stroma. J Clin Endocrinol Metabol 1997, 82:508-513.
34. Usmani B, Harden B, Maitland NJ, Turner AJ. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci 2002, 103:3145-3175.